NCT05351879 - Evaluation of a Booster Administration of GAD-alum (Diamyd®) in Individuals With Type 1 Diabetes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 9, 2022

Primary Completion Date

August 29, 2023

Study Completion Date

August 29, 2023

Conditions

Diabetes Mellitus, Type 1

Interventions

BIOLOGICAL

GAD-alum (Diamyd) 40 μg/mL

Recombinant Human Glutamic Acid Decarboxylase (rhGAD65) adsorbed to Alhydrogel at a concentration of 40 μg/mL and is given as a sterile solution for intralymphatic injection

Trial Locations (1)

581 85

Kliniska Forskningsenheten (Hudmottagningen), Universitetssjukhuset Linköping, Linköping